indazoles has been researched along with Cells, Neoplasm Circulating in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agelaki, S; Fountzilas, G; Georgoulias, V; Hartabilas, E; Karavassilis, V; Katsaounis, P; Kentepozidis, N; Koinis, F; Kotsakis, A; Messaritakis, I; Peroukidis, S; Samantas, E; Varthalitis, II | 1 |
| Berglund, UW; Blackhall, F; Chester, CPE; Dive, C; Frese, KK; Gorgoulis, VG; Gulati, S; Helleday, T; Kalderen, C; Khandelwal, G; Lallo, A; Miller, C; Pateras, IS; Pham, TM; Schenk, MW | 1 |
| Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
| Funahashi, Y; Gotoh, M; Inoue, S; Kato, M; Maeda, M; Sassa, N | 1 |
| Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
| Hamada, A; Inoue, T; Kamba, T; Kobayashi, T; Matsui, Y; Negoro, H; Ogawa, O; Sugino, Y; Terada, N; Yamasaki, T; Yoshimura, K | 1 |
| Alonso-Gordoa, T; Apellaniz-Ruiz, M; Capdevila, J; Carrato, A; Casanovas, O; Castellano, D; Díez, JJ; Durán, I; Earl, J; Escudero, P; Fuster, J; García-Carbonero, R; García-Donas, J; Grande, E; Ortega, L; Rodriguez-Antona, C; Sastre, J; Sevilla, I; Teulé, A | 1 |
| Bardelli, A; Bartolini, A; Bianchi, AS; Cam, N; Corti, G; Crisafulli, G; Di Nicolantonio, F; Lazzari, L; Li, G; Misale, S; Mussolin, B; Novara, L; Patel, R; Rospo, G; Russo, M; Shoemaker, R; Siena, S; Siravegna, G; Wei, G; Wild, R; Yan, S | 1 |
| Fujisaki, A; Komatsubara, M; Kurokawa, S; Morita, T; Yamazaki, M | 1 |
| Baruchel, S; Kerbel, RS; Kumar, S; Man, S; Mokhtari, RB; Oliveira, ID; Sheikh, R; Wu, B; Xu, P; Yeger, H; Zhang, L | 1 |
1 review(s) available for indazoles and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
2 trial(s) available for indazoles and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carboplatin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Indazoles; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Pyrimidines; Small Cell Lung Carcinoma; Sulfonamides; Treatment Outcome | 2017 |
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Indazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplastic Cells, Circulating; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Proportional Hazards Models; Pyrimidines; Sulfonamides; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2015 |
7 other study(ies) available for indazoles and Cells, Neoplasm Circulating
| Article | Year |
|---|---|
Ex vivo culture of cells derived from circulating tumour cell xenograft to support small cell lung cancer research and experimental therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Humans; Indazoles; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, SCID; Neoplasms, Experimental; Neoplastic Cells, Circulating; Small Cell Lung Carcinoma; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2019 |
Efficacy of pre-surgical axitinib for shrinkage of inferior vena cava thrombus in a patient with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Hepatic Veins; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
[Presurgical treatment of axitinib reduced operation risk by downsizing the vena cava tumor thrombus in advanced renal cell carcinomas: two case reports].
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Preoperative Care; Protein Kinase Inhibitors; Vena Cava, Inferior | 2014 |
Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.
Topics: Animals; Benzamides; Catalytic Domain; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Rearrangement; Humans; Indazoles; Mice; Mutation; Neoplasm Transplantation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Receptor, trkA | 2016 |
Tumor Thrombus of Renal Cell Carcinoma Extending Into the Inferior Vena Cava, Ovarian Vein, and Ureter Treated With Neoadjuvant Axitinib.
Topics: Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Ovary; Ureteral Neoplasms; Veins; Vena Cava, Inferior | 2016 |
Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Topics: Administration, Metronomic; Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Endothelial Cells; Humans; Indazoles; Mice; Mice, Inbred NOD; Mice, SCID; Microvessels; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neuroblastoma; Osteosarcoma; Pyrimidines; Random Allocation; Rhabdomyosarcoma; Stem Cells; Sulfonamides; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays | 2011 |